Early Cancer Detection: Johns Hopkins Blood Test
- A new study indicates that genetic material shed by tumors can be identified in the bloodstream up to three years before a cancer diagnosis.The research, conducted by investigators...
- Yuxuan Wang, assistant professor of oncology at the Johns Hopkins University School of Medicine and lead author, expressed surprise at the early detection capability."Three years earlier provides time...
- Researchers analyzed plasma samples collected for the Atherosclerosis Risk in communities (ARIC) study,a National Institutes of Health-funded project focused on cardiovascular disease risk factors.
Early cancer detection may be achievable years before a diagnosis, thanks to a groundbreaking study from Johns Hopkins. This research reveals that tumor DNA is detectable in the bloodstream up to three years ahead of a cancer diagnosis, offering the possibility of earlier and more effective interventions. Scientists analyzed blood samples, employing advanced sequencing to identify cancer-derived mutations, demonstrating the potential of multi-cancer early detection (MCED) tests and the important opportunity to improve patient outcomes. With further studies planned to determine appropriate follow-up care, this study underscores the power of cutting-edge research in oncology. news Directory 3 provides the latest updates. Discover what’s next in the fight against cancer.
Blood Test Shows Promise for Early Cancer Detection
Updated June 13,2025
A new study indicates that genetic material shed by tumors can be identified in the bloodstream up to three years before a cancer diagnosis.The research, conducted by investigators at Johns Hopkins, suggests the potential for earlier intervention and more effective treatment.
Yuxuan Wang, assistant professor of oncology at the Johns Hopkins University School of Medicine and lead author, expressed surprise at the early detection capability.”Three years earlier provides time for intervention,” Wang said. ”The tumors are likely to be much less advanced and more likely to be curable.” The findings were published in Cancer Finding.
Researchers analyzed plasma samples collected for the Atherosclerosis Risk in communities (ARIC) study,a National Institutes of Health-funded project focused on cardiovascular disease risk factors. They examined blood samples from 26 ARIC participants who were diagnosed with cancer shortly after sample collection,comparing them to 26 similar participants without a cancer diagnosis. Highly sensitive sequencing techniques were employed to detect cancer-derived mutations.
Of the 52 participants, eight tested positive on a multicancer early detection (MCED) laboratory test at the time of blood sample collection. All eight were diagnosed with cancer within four months. Further analysis of blood samples collected 3.1 to 3.5 years prior to diagnosis from six of these individuals revealed tumor-derived mutations in four cases.
“This study shows the promise of MCED tests in detecting cancers very early, and sets the benchmark sensitivities required for their success,” said Bert Vogelstein, Clayton Professor of Oncology, co-director of the Ludwig Center at Johns Hopkins and a senior author on the study.
“Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome,” added Nickolas Papadopoulos, professor of oncology, ludwig Center investigator and senior author of the study. “of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers.”
What’s next
Further research is needed to determine the appropriate clinical follow-up for individuals who test positive for early cancer detection. The study highlights the potential of multi-cancer early detection tests in improving cancer management and outcomes.